Program
atogepant
Also written as “Atogepant”, “Atogepant 60 mg” and “Atogepant 30 mg”.
Its studies are mostly in Migraine Disorders, led by AbbVie.
Furthest: phase 4, since Feb 22, 202219 company-led studies, 4 open or runningNext primary completion: Mar 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 194 open or running | phase 4since Feb 22, 2022 | Jul 26, 2016 | Mar 2028phase 3 · NCT05711394 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 26, 2016.
- Feb 25, 2019Phase 3 study in Chronic MigraineNCT03855137 · 778 enrolled · United States, Australia, Canada and more
- May 3, 2019Phase 3 study in Migraine DisordersNCT03939312 · 685 enrolled · United States
- Jun 16, 2020Phase 3 study in Chronic MigraineNCT04437433 · 186 enrolled · Japan
- Dec 21, 2020Phase 3 study in Episodic MigraineNCT04686136 · 596 enrolled · United States, Canada, Czechia and more
- Feb 2, 2021Phase 3 study in Episodic MigraineNCT04740827 · 315 enrolled · United States, Australia, Canada and more
- Mar 24, 2021Phase 1 study in Migraine DisordersNCT04818515 · 26 enrolled · United States
- Apr 1, 2021Phase 3 study in Migraine DisordersNCT04829747 · 3 enrolled · China
- Jan 19, 2022Phase 3 study in Migraine DisordersNCT05216263 · 75 enrolled · United States
- Feb 22, 2022Phase 4 study in Episodic MigraineNCT05264129 · 263 enrolled · United States
- Jan 24, 20232 phase 3 studiesNCT05707949, NCT05711394
- May 8, 2023Phase 3 study in Migraine DisordersNCT05861427 · 524 enrolled · Japan
- May 30, 2023Phase 1 study in Healthy VolunteersNCT05892757 · 24 enrolled · United States
- Jan 28, 2024Phase 3 study in Migraine DisordersNCT06241313 · 2,158 enrolled · Belgium, China, Czechia and more
- Jan 29, 20252 phase 3 studiesNCT06806293, NCT06810505
Ahead
- Mar 2028Primary completion: phase 3 study in Episodic MigraineNCT05711394
- Mar 2031Primary completion: phase 3 study in Migraine DisordersNCT06810505
- Apr 2032Primary completion: phase 3 study in Migraine ProphylaxisNCT05707949
TargetBeta
“An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the preventive treatment of migraines”NCIt, by rule
“Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ubrogepantrule | AbbVie | phase 4 | 13 |
| zavegepantrule | Pfizer | phase 3 | 13 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06810505Migraine Disorders · United States, Canada, Denmark and more | 3 | Recruiting | Mar 2031 | 420 |
| NCT06806293Menstrual Migraine (MM) · China, Czechia, Germany and more | 3 | Active, not recruiting | Jun 29, 2026 | 468 |
| NCT06241313Migraine Disorders · Belgium, China, Czechia and more | 3 | Completed | Jul 7, 2025 | 2,158 |
| NCT05892757Healthy Volunteers · United States | 1 | Completed | Feb 22, 2024 | 24 |
| NCT05861427Migraine Disorders · Japan | 3 | Completed | Mar 1, 2025 | 524 |
| NCT05711394Episodic Migraine · United States, Belgium, Canada and more | 3 | Recruiting | Mar 2028 | 450 |
| NCT05707949Migraine Prophylaxis · United States, Belgium, Canada and more | 3 | By invitation | Apr 2032 | 650 |
| NCT05264129Episodic Migraine · United States | 4 | Completed | Apr 4, 2023 | 263 |
| NCT05216263Migraine Disorders · United States | 3 | Completed | May 2, 2025 | 75 |
| NCT04829747Migraine Disorders · China | 3 | Completed | Jan 20, 2022 | 3 |
| NCT04818515Migraine Disorders · United States | 1 | Completed | Jun 18, 2021 | 26 |
| NCT04740827Episodic Migraine · United States, Australia, Canada and more | 3 | Completed | Aug 4, 2022 | 315 |
| NCT04686136Episodic Migraine · United States, Canada, Czechia and more | 3 | Completed | Oct 20, 2025 | 596 |
| NCT04437433Chronic Migraine · Japan | 3 | Completed | Jun 11, 2024 | 186 |
| NCT03939312Migraine Disorders · United States | 3 | Completed | Mar 31, 2021 | 685 |
| NCT03855137Chronic Migraine · United States, Australia, Canada and more | 3 | Completed | Jan 20, 2022 | 778 |
| NCT03777059Migraine Disorders · United States | 3 | Completed | Jun 19, 2020 | 910 |
| NCT03700320Episodic Migraine · United States | 3 | Completed | May 21, 2020 | 744 |
| NCT02848326Migraine Disorders · United States | 3 | Completed | Apr 2, 2018 | 834 |
How it is read
Names in the registry
- “Atogepant”, 15 entries
- “Atogepant 60 mg”, 4 entries
- “Atogepant 30 mg”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.